Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1995 Nov;41(6):348–354. doi: 10.1007/BF01526554

Characterisation of the anti-bladder-cancer monoclonal antibody BLCA-8: Identification of its antigen as a neutral glycolipid

Elizabeth A Kingsley 1,✉, Teresa E Carter 1,2, Kevin D Barrow 2, Pamela J Russell 1
PMCID: PMC11037576  PMID: 8635192

Abstract

A monoclonal antibody, BLCA-8, was raised against the human bladder cancer cell line, UCRU-BL-17CL. By flow cytometry and immunoperoxidase staining, this antibody was found to possess high specificity for bladder tumours, some reactivity with fetal tissues, and no reactivity with normal bladder, or any normal or malignant tissue. This high specificity and the stability of the antigen to the urinary environment suggest that BLCA-8 may have potential for use as an anti-bladder-cancer therapeutic agent. By thin-layer chromatography and autoradiography, BLCA-8 was found to bind four components within the neutral lipid fraction of a bladder cancer cell line, UCRU-BL-17/23α. These components hadR F values of 0.22, 0.16/0.15 (doublet), 0.12 and 0.08, and migrated below globoside, indicating the presence of more than four sugars. By enzyme-linked immunosorbant assay and thin-layer chromatography it was found that the binding of BLCA-8 to the lipid extract was increased by both mild alkaline hydrolysis and enzymatic treatments, indicating that adjacent phospholipids and glycolipids interfere with the accessibility of the antibody-binding site. Full biochemical characterisation of the BLCA-8 antigen is currently underway.

Key words: Bladder cancer, Monoclonal antibody, Neutral glycolipid antigen, Antigen accessibility

References

  • 1.Kohler G, Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  • 2.Goldenberg D. Monoclonal antibodies in cancer detection and therapy. Am J Med. 1993;94:297. doi: 10.1016/0002-9343(93)90062-t. [DOI] [PubMed] [Google Scholar]
  • 3.Goldenberg D. Radioimmunotherapy of cancer: arming the missiles. J Nucl Med. 1992;33:1110. [PubMed] [Google Scholar]
  • 4.Russell P, Kingsley E, Humphreys J, Davis K, Hanley J, O'Grady H, Garsia R, Pearce N. Can monoclonal antibodies be used for radioimmunotherapy of superficial bladder cancers? Cancer Forum. 1993;17:123. [Google Scholar]
  • 5.Walker KZ, Russell PJ, Kingsley EA, Philips J, Raghavan D. Detection of malignant cells in voided urine from patients with bladder cancer, a novel monoclonal assay. J Urol. 1989;142:1578. doi: 10.1016/s0022-5347(17)39172-3. [DOI] [PubMed] [Google Scholar]
  • 6.Russell PJ, Jelbart M, Wills E, Singh S, Wass J, Wotherspoon J, Raghavan D. Establishment and characterization of a new human bladder cancer cell line showing features of squamous and glandular differentiation. Int J Cancer. 1988;41:74. doi: 10.1002/ijc.2910410115. [DOI] [PubMed] [Google Scholar]
  • 7.Boux HA, Raison RL, Walker KZ, Hayden GE, Basten A. A tumor-associated antigen specific for human kappa myeloma cells. J Exp Med. 1983;158:1769. doi: 10.1084/jem.158.5.1769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Harlow E, Lane D. Antibodies: a laboratory manual. New York: Cold Spring Harbor Laboratory; 1988. p. 359. [Google Scholar]
  • 9.Koscielak J, Miller-Podraza H, Zdebska E. Isolation of poly(glycosyl)ceramides with A, B, H, and I blood-group activities. Methods Enzymol. 1978;50:211. doi: 10.1016/0076-6879(78)50022-0. [DOI] [PubMed] [Google Scholar]
  • 10.Stein J, Smith G. Glycolipids. Tech Lipid Membr Biochem B. 1982;404:1. [Google Scholar]
  • 11.Ariga T, Macala LJ, Saito M, Margolis RK, Greene LA, Margolis RU, Yu RK. Lipid composition of PC12 pheochromocytoma cells: characterization of globoside as a major neutral glycolipid. Biochemistry. 1988;27:52. doi: 10.1021/bi00401a010. [DOI] [PubMed] [Google Scholar]
  • 12.Vance DE, Sweeley CC. Quantitative determination of the neutral glycosyl ceramides in human blood. J Lipid Res. 1967;8:621. [PubMed] [Google Scholar]
  • 13.Kundu SK. Thin-layer chromatography of neutral glycosphingolipids and gangliosides. Methods Enzymol. 1981;72:185. doi: 10.1016/s0076-6879(81)72012-3. [DOI] [PubMed] [Google Scholar]
  • 14.Fraker PJ, Speck JC., Jr Protein and cell membrane iodinations with a sparingly soluble chloroamide 1,3,4,6-tetrachloro-3a, 6a-diphenylglycoluril. Biochem Biophys Res Commun. 1978;80:849. doi: 10.1016/0006-291x(78)91322-0. [DOI] [PubMed] [Google Scholar]
  • 15.Ravindrath MH, Morton DL, Irie RF. An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res. 1989;49:3891. [PubMed] [Google Scholar]
  • 16.Bamias A, Keane P, Krausz T, Williams G, Epenetos AA. Intravesical administration of radiolabeled antitumor monoclonal antibody in bladder carcinoma. Cancer Res. 1991;51:724. [PubMed] [Google Scholar]
  • 17.Bamias A, Bowles MJ, Krausz T, Williams G, Epenetos AA. Intravesical administration of indium-111-labelled HMFG2 monoclonal antibody in superficial bladder carcinomas. Int J Cancer. 1991;54:899. doi: 10.1002/ijc.2910540604. [DOI] [PubMed] [Google Scholar]
  • 18.Russell PJ, Plomley J, Raghavan D. The use of monoclonal antibodies for the diagnosis and therapy of bladder cancer. Br J Urol. 1993;71:121. doi: 10.1111/j.1464-410x.1993.tb15903.x. [DOI] [PubMed] [Google Scholar]
  • 19.Kannagi R, Stroup R, Cochran NA, Urdal DL, Young WW, Jr, Hakomori S. Factors affecting expression of glycolipid tumor antigens: influence of ceramide composition and coexisting glycolipid on the antigenicity of gangliotriaosylceramide in murine lymphoma cells. Cancer Res. 1983;43:4997. [PubMed] [Google Scholar]
  • 20.Ugorski M, Pahlsson P, Dus D, Nilsson B, Radzikowski C. Glycosphingolipids of human urothelial cell lines with different grades of transformation. Glyconj J. 1989;6:303. doi: 10.1007/BF01047850. [DOI] [PubMed] [Google Scholar]
  • 21.Gray GM. A comparison of the glycolipids found in different strains of ascites tumor cells in mice. Nature. 1965;207:505. doi: 10.1038/207505a0. [DOI] [PubMed] [Google Scholar]
  • 22.Ford SA, Russell PJ, Jelbart M, Raghavan D. Detection of tumor-associated membrane proteins in prostate and bladder carcinomas by means of protein blotting. Urol Res. 1989;17:305. doi: 10.1007/BF00262988. [DOI] [PubMed] [Google Scholar]
  • 23.Orntoft TF. Carbohydrate changes in bladder carcinomas. APMIS. 1992;100(Suppl 27):181. [PubMed] [Google Scholar]
  • 24.Meldgaard P, Holmes EH, Bennett EP, Clausen H, Zeuthen J, Wolf H, Orntoft TF. Blood group ABO-related glycosylation of urothelial cell lines: immunocytological, enzymatic, and genetic characterisation. Cancer Res. 1994;54:2440. [PubMed] [Google Scholar]
  • 25.Lloyd KO, Gordon CM, Thampoe IJ, DiBenedetto C. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells. Cancer Res. 1992;52:4948. [PubMed] [Google Scholar]
  • 26.Jamasbi RJ, Wan X, Stoner GD. Epitope masking of rat esophageal carcinoma tumor-associated antigen by certain coexisting glycolipid and phospholipid molecules: a potential mechanism for tumor cell escape from the host immune responses. Cancer Immunol Immunother. 1994;38:99. doi: 10.1007/BF01526204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Hakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res. 1989;52:257. doi: 10.1016/s0065-230x(08)60215-8. [DOI] [PubMed] [Google Scholar]
  • 28.Paulson JC, Colley KJ. Glycosyltransferases. Structure, localization, and control of cell type-specific glycosylation. J Biol Chem. 1989;264:17615. [PubMed] [Google Scholar]
  • 29.Yamamoto F, Clausen H, White T, Marken J, Hakomori S. Molecular genetic basis of the histo-blood group ABO system. Nature. 1990;345:229. doi: 10.1038/345229a0. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES